Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd., is pleased to announce that its Grangemouth, UK facility has received updated MHRA GMP certificates following a successful compliance report and desktop inspection. These certificates encompass all activities within the facility’s Helix building, which specializes in clinical and […]
Post Type Archives: News
Inizio Evoke launches Predictev™, a query-driven predictive intelligence engine for life-sciences commercial teams
Inizio Evoke introduced Predictev™, a query-driven predictive intelligence engine that puts actionable foresight directly in clients’ hands. Users ask questions in plain language and receive forecasts, scenario comparisons, and recommended next steps—spanning brand strategy, field optimization, and omnichannel engagement. Predictev™ is powered by Inizio Evoke’s commercial intelligence platform Cognitev™ and its more than 35 million […]
Johnson & Johnson to Acquire Halda Therapeutics for $3.05 Billion
Johnson & Johnson announced a definitive agreement to acquire Halda Therapeutics, a clinical-stage biotechnology company, on November 17, 2025. Johnson & Johnson will pay $3.05 billion for Halda, which owns a proprietary Regulated Induced Proximity Targeting Chimera (RIPTAC) platform that it is using to develop oral, targeted therapies for multiple types of solid tumors. According […]
First Pertzumab Biosimilar Receives FDA Approval
Shanghai Henlius Biotech, a biopharmaceutical company developing biologics, and Organon, a healthcare company focused on addressing women’s health needs, announced FDA approval of Poherdy (pertuzumab-dpzb) as an interchangeable biosimilar to Perjeta (pertuzumab) on November 17, 2025. Pertuzumab-dpzb, a HER2/neu receptor antagonist, is the first and only approved biosimilar for pertuzumab in the United States. Pertuzumab-dpzb […]
Almac announces multi-million-pound investment in Singapore
Almac Group has announced a multi-million-pound investment to expand its facility in Singapore, as the company marks ten years of operations in the country. The investment by Almac Clinical Services is part of a long-term commitment to expand warehouse capacity in Singapore and increase regional clinical supply management expertise to address client demand. This initiative […]
Merck to Acquire Cidara Therapeutics in $9.2 Billion Deal
Merck, known as MSD outside of the United States and Canada, and Cidara Therapeutics, a biotechnology company developing drug-Fc conjugate (DFC) therapeutics, announced a definitive merger agreement on November 14th, 2025. According to a company press release, Merck will pay $221.50 per share, or approximately $9.2 billion, in cash to acquire Cidara Therapeutics. The transaction […]
FDA Approves Acute Myeloid Leukemia Treatment
Kura Oncology, a biopharmaceutical company focused on precision medicines for cancer treatment, and Kyowa Kirin, a specialty pharmaceutical company, announced FDA approval of Komzifti (ziftomenib) for adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) on November 13th, 2025. This approval grants patients with a susceptible NPM1 mutation, who have no satisfactory alternative […]
Bristol Myers Squibb and Sarah Cannon Research Institute Announce Clinical Trial Collaboration
Bristol Myers Squibb announced a strategic collaboration with the Sarah Cannon Research Institute (SCRI), an oncology research organization conducting community-based clinical trials, on November 12th, 2025. According to a company press release, the collaboration aims to launch various clinical trials from Bristol Myers’ oncology pipeline at SCRI’s network of more than 200 locations across over […]
General Proximity Announces Multi-Target Oncology Collaboration with Daiichi Sankyo
General Proximity, a biotechnology company focused on induced proximity medicines, announced a multi-target oncology collaboration with Daiichi Sankyo on November 12th, 2025. The collaboration will see General Proximity use its OmniTAC platform to discover and characterize novel effector-target pairs for Daiichi Sankyo, with the ultimate aim of developing induced proximity therapeutics for undisclosed oncological conditions. […]
BostonGene and Kyoto University Enter Precision Drug Development Collaboration
BostonGene and Kyoto University announced a precision drug development partnership on November 12th, 2025. According to a company press release, the goal of the research collaboration is to develop advanced biological signatures for the purposes of enhancing targeted treatment strategies in patients with esophageal squamous cell carcinoma (ESCC), the most common variation of esophageal cancer. […]